Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Published 2014 View Full Article

Authors

Keywords

Journal

LANCET ONCOLOGY

Volume 15, Issue 2, Pages 143-155

Publisher

Elsevier BV

Online

2014-01-09

DOI

10.1016/s1470-2045(13)70586-2

Ask authors/readers for more resources

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

LANCET ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Create your own webinar

Ask a Question. Answer a Question.